secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005020
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025
--------------------------------------------------------------------------------

- First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).
- Interim data from Part 1 (single ascending doses) expected H2 2025; study completion anticipated in 2026.
- Pipeline update: Korro targets 3 candidates, 2 tissue types, single platform (3-2-1 strategy) by 2027.
- Novo Nordisk partnered program in cardiometabolic indication progressing towards clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/0001193125-25-005020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/d915237d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer